Analyst Price Targets — CRVO
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| November 5, 2025 11:14 am | Raghuram Selvaraju | H.C. Wainwright | $25.00 | $7.02 | TheFly | CervoMed upgraded to Buy from Neutral at H.C. Wainwright |
| October 17, 2025 10:25 am | — | Roth Capital | $20.00 | $7.60 | TheFly | CervoMed price target raised to $20 from $16 at Roth Capital |
| August 12, 2025 11:59 am | Boobalan Pachaiyappan | Roth Capital | $16.00 | $9.41 | TheFly | CervoMed price target lowered to $16 from $20 at Roth Capital |
| September 18, 2024 5:17 am | Danill Gataulin | Loop Capital Markets | $16.32 | $4.79 | StreetInsider | Chardan Capital Markets Starts CervoMed (CRVO) at Buy |
| September 18, 2024 5:05 am | Daniil Gataulin | Chardan Capital | $16.32 | $4.79 | TheFly | CervoMed initiated with a Buy at Chardan |
| April 8, 2024 7:06 am | Sumant Kulkarni | Canaccord Genuity | $19.29 | $6.08 | StreetInsider | CervoMed (CRVO) PT Raised to $65 at Canaccord Genuity |
Latest News for CRVO
Results consistent with pre-clinical studies demonstrating that, in the early stages of the neurodegenerative process, disease progression in the basal forebrain is reversible
Update will include new MRI analyses from the Phase 2b RewinD-LB clinical trial, status of global regulatory discussions, and finalized Phase 3 trial design
CIBC Private Wealth Group LLC cut its stake in Illumina, Inc. (NASDAQ: ILMN) by 4.1% in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 299,361 shares of the life sciences company's stock after selling 12,818 shares during the period. CIBC
New analyses show DLB patients with lower plasma pTau181 levels — indicating an earlier stage of disease and absence of Alzheimer's disease (AD) co-pathology — experienced greater clinical benefit with neflamapimod in Phase 2b clinical trial
Illumina (NASDAQ: ILMN - Get Free Report) and CervoMed (NASDAQ: CRVO - Get Free Report) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, institutional ownership, valuation, earnings, dividends, analyst recommendations and risk. Analyst Ratings This is a summary of current recommendations and
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for CRVO.
U.S. House Trading
No House trades found for CRVO.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.